[Skip to Navigation]
December 3, 2020

Teprotumumab for Optic Neuropathy in Thyroid Eye Disease

Author Affiliations
  • 1W.K. Kellogg Eye Center, Department of Ophthalmology and Visual Sciences, University of Michigan, Ann Arbor
  • 2now with the Medical Eye Center, Manchester, New Hampshire
  • 3Division of Metabolism and Diabetes, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor
JAMA Ophthalmol. 2021;139(2):244-247. doi:10.1001/jamaophthalmol.2020.5296

Thyroid eye disease (TED) presents with varying degrees of proptosis, eyelid retraction, diplopia, congestion, and infrequently, compressive optic neuropathy (CON). The US Food and Drug Administration (FDA) recently approved teprotumumab for the treatment of TED. The effectiveness of teprotumumab for CON is currently unclear. In this study, we report the clinical course of a patient with TED and early CON who improved after a single teprotumumab infusion, with sustained improvement at 25 weeks following the initial dose.

Add or change institution